CI — The Cigna Group, the Connecticut-based health services company — carries broad but divided sell-side coverage. Roughly two dozen analysts tracked by S&P Global average a price target near $342, a figure that rounds to the $340 central target used here. The spread between the lowest ($288, Jefferies) and highest ($400, UBS) targets is unusually wide, which is itself a signal about how uncertain the stock forecast is right now.
The bullish camp emphasizes Cigna's specialty pharmacy and care-services momentum. Piper Sandler raised its target to $370 from $346 after the company's Investor Day, citing the long-term adjusted EPS CAGR (compound annual growth rate) of 10%–14% and a 2030 adjusted EPS floor of $45. Bernstein lifted its target to $387, UBS reiterated Buy with a $400 target, and Oppenheimer, Guggenheim, RBC, Truist, JPMorgan, and Morgan Stanley all hold targets in the $330–$375 zone.
The cautious camp focuses on the PBM transition. Jefferies cut its target to $288 from $307 while keeping a Hold rating, and Evercore ISI initiated coverage at In-line with a $290 target, pointing to risk as Cigna's PBM moves toward a no-rebate model. Raymond James trimmed its target to $320. This split is the core of the analyst consensus debate: the average analyst price target implies meaningful upside, but it is not a guarantee.
At a recent close of $270.53, CI would need to rise about 26% to reach $340. That is a substantial move, not a trivial one, and it comes after a period of underperformance — the stock is trading below its 52-week high of roughly $312, with a 52-week range near $239.51 to $312.18. The shares also carry a modest trailing P/E (price-to-earnings ratio) around 11 and a dividend yield above 2%.
The path toward the target would likely require two things to work together: continued earnings delivery, and a reduction in the regulatory discount that has weighed on the PBM business. Cigna's second-quarter results beat expectations, with adjusted EPS of $7.78 versus a roughly $7.59 estimate, and the company raised its full-year outlook. If execution stays on track and the 2030 EPS floor gains credibility, the valuation multiple could expand — but that is an assumption, not a certainty.
The most relevant technical levels are durable ones. The 52-week high near $312 is the first major resistance level that CI would need to reclaim before a move toward $340 becomes realistic. Below the current price, the 52-week low near $239 to $244 marks a key support level, with traders also watching the mid-$260s as a nearer-term floor. The long-term trend structure remains mixed: the stock has pulled back meaningfully from prior highs, so the market has yet to establish a sustained uptrend.
Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms can differ. Investors should watch the next quarterly earnings report (scheduled for early November 2026), any updates to guidance, and further analyst target revisions. Regulatory developments around PBMs, FTC actions, and the Express Scripts transition are equally important, as are membership trends and cash-flow quality. None of these should be treated as a definitive timing signal.
Traders tracking CI can complement fundamental research with automated tools such as Tickeron's AI Daily Buy/Sell Signals. This system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Rather than replacing human judgment, it is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently. If you want to see how AI interprets the current setup for CI, explore the AI Daily Buy/Sell Signals to stay ahead of evolving market conditions.
The question of whether The Cigna Group can reach $340 is really a question about whether earnings momentum can overcome a regulatory discount. The $340 central target, derived from an analyst mean near $342, sits about 26% above the current price — a substantial but not extreme gap. Support comes from strong recent results, a clear long-term growth roadmap, and a cheap valuation. The obstacles are equally real: PBM regulation, the Express Scripts rebate transition, and litigation risk keep the widest target range in the group. With targets spanning $288 to $400, there is genuine disagreement among analysts. Investors should monitor earnings, guidance, and regulatory headlines rather than treat any single price forecast as a foregone conclusion.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CI has been loosely correlated with CVS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CI jumps, then CVS could also see price increases.